ArticlePLoS neglected tropical diseases2026
Local heterogeneity in Lassa fever serology in rural Nigeria: Implications for vaccine trial site selection.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
introductionLassa virus (LASV) causes significant morbidity in West Africa, yet vaccine trial planning is hampered by a lack of high-resolution, community-level seroprevalence data. We aimed to characterize the fine-scale spatial and demographic heterogeneity of LASV exposure in rural Nigeria to inform site selection strategies.
methodsWe conducted a cross-sectional serosurvey across nine villages in three Nigerian states (Benue, Ebonyi, and Cross River). We recruited 1,874 individuals and tested for LASV IgG using the highly specific Panadea LASV IgG ELISA. We employed Bayesian hierarchical models to estimate seroprevalence and investigated 21 pre-specified demographic, environmental, and behavioral risk factors for association with seropositivity. Village-specific transmission dynamics were explored using Bayesian generalized additive models for age-stratified seroprevalence.
resultsThe overall model-based IgG seroprevalence was 3.2% (95% CrI: 2.5-4.0%). We observed marked fine-scale heterogeneity, with village-level estimates ranging from 0.8% to 6.5%. Age-seroprevalence curves suggested? divergent transmission dynamics, ranging from cumulative endemic exposure to recent focal outbreaks in younger cohorts. Likely constrained by low overall prevalence and high exposure ubiquity, univariable analyses detected no strong or consistent associations between seropositivity and the 21 pre-specified risk factors, including rodent consumption and agricultural practices. No significant village-wide spatial clustering of seropositive households was observed via Local Getis-Ord (Gi*). DISCUSSION: LASV exposure in rural Nigeria is characterized by low overall prevalence punctuated by significant hyper-local variation. The lack of consistent individual-level risk factors and the divergent age-exposure profiles suggest that risk may be influenced by stochastic, localized ecological drivers or obscured by the temporal misalignment of cross-sectional surveys. Vaccine trial site selection must move beyond regional incidence data to incorporate interdisciplinary, One Health metrics including high-resolution human serosurveillance and longitudinal reservoir monitoring to identify active transmission hotspots.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.